These findings suggest that members of this pathway – HOXA10, RUNX2 isoform II, and PRDX2 – could be new therapeutic targets for OSCC, and potentially other types of cancer that are also associated with high levels of RUNX2 isoform II. Here, PRDX2 is linked to cancer.